Drug target identified for chemotherapy-resistant ovarian, breast cancer

People who inherit a faulty copy of the so-called "breast cancer genes" BRCA1 and BRCA2 are at high risk of cancer. About 10 percent of breast cancer cases and 15 percent of ovarian cancers can be traced back to a flaw in one of these genes. A class of drugs known as PARP inhibitors was designed to target tumors with defective BRCA genes.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news